September 1, 2023Journal for ImmunoTherapy of CancerOpen Access

Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis

View Full Paper

Ask AI

Bookmark

Abstract

Taken together, our results demonstrated the role of TCA cycle in immune checkpoint blockade and provided a novel combination strategy for anti-PD-1 immunotherapy in melanoma treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liu et al. (2023) studied this question.

synapsesocial.com/papers/69dcaa10d4d0de07d11336c3 https://doi.org/10.1136/jitc-2023-007146

View Full Paper

Ask AI

Bookmark

Abstract

Taken together, our results demonstrated the role of TCA cycle in immune checkpoint blockade and provided a novel combination strategy for anti-PD-1 immunotherapy in melanoma treatment.

Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis

Abstract

Discussion

Cite This Study

Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis

Abstract

Discussion

Cite This Study

Keep reading

Keep reading